FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma is the most common lymphoid malignancy, as it accounts for approximately one third of all patient cases of non-Hodgkin’s lymphoma. Patients with diffuse large B-cell lymphoma have markedly different treatment outcomes, suggesting a need for reliable prognostic factors a...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Hematop
Asıl Yazarlar: Danilova, Olga V., Dumont, Larry J., Levy, Norman B., Lansigan, Frederick, Kinlaw, William B., Danilov, Alexey V., Kaur, Prabhjot
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2013
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4415532/
https://ncbi.nlm.nih.gov/pubmed/25937841
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller